ESR1 and breast carcinoma: Despite conflicting reports, some epidemiological studies show that regular use of COX-2 inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the risk of developing ERα-positive breast cancers, but not ERα-negative cancers [116].